Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism

Overview

Topical brimonidine is a recently introduced alpha 2 receptor agonist which is used in the therapy of intraocular pressure (IOP) reduction in patients with open angle glaucoma. Although adequate IOP reduction is achieved in many patients there is a considerable degree of variability in IOP reduction among subjects. The reason for this interindividual variability is not entirely clear. Obviously differences in pharmacokinetic properties due to variable penetration of the drug through the cornea may be responsible. Alternatively, polymorphisms of the alpha-2 receptor may account for the differences in IOP-lowering efficacy of topical brimonidine. This hypothesis is tested in the present study. Polymorphisms of the alpha-2 receptor have been described in a number of previous studies. In addition, polymorphisms in the alpha-2 receptor gene have been shown to be functionally important, particularly a polymorphism of the alpha-2B receptor, which has a high allele frequency in caucasians.

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2014

Interventions

  • Drug: Brimonidine 0.2 %
    • Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye

Arms, Groups and Cohorts

  • Active Comparator: 1
    • homozygote mutant: Insertion/Insertion (40 patients)
  • Active Comparator: 2
    • homozygote mutant: Deletion/Deletion (40 patients)

Clinical Trial Outcome Measures

Primary Measures

  • Intraocular pressure (IOP)
    • Time Frame: in total 10 minutes
  • alpha-2B receptor genotyping
    • Time Frame: 20 minutes

Participating in This Clinical Trial

Inclusion Criteria

  • Men aged between 19 and 35 years, nonsmokers – Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant – IOP between 12 and 16 mmHg – Normal ophthalmic findings, ametropia < 3 Dpt. – Results of alpha-2B receptor genotyping; subjects who fall within one of the following groups: group 1: homozygote mutant: I/I (n=40); group 2: homozygote mutant: D/D (n=40) Exclusion Criteria:

  • Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study – Treatment in the previous 3 weeks with any drug – Symptoms of a clinically relevant illness in the 3 weeks before the first study day – History of hypersensitivity to the trial drug or to drugs with a similar chemical structure – History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with, distribution, metabolism or excretion of study drugs – Blood donation during the previous 3 weeks

Gender Eligibility: Male

Minimum Age: 19 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Medical University of Vienna
  • Provider of Information About this Clinical Study
    • Gabriele Fuchsjäger-Mayrl, MD, Department of Clinical Pharmacology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.